Literature DB >> 17043312

Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

Steve Bilodeau1, Sophie Vallette-Kasic, Yves Gauthier, Dominique Figarella-Branger, Thierry Brue, France Berthelet, André Lacroix, Dalia Batista, Constantine Stratakis, Jeanette Hanson, Björn Meij, Jacques Drouin.   

Abstract

Negative feedback regulation of the proopiomelanocortin (POMC) gene by the glucocorticoid (Gc) receptor (GR) is a critical feature of the hypothalamo-pituitary-adrenal axis, and it is in part exerted by trans-repression between GR and the orphan nuclear receptors related to NGFI-B. We now show that Brg1, the ATPase subunit of the Swi/Snf complex, is essential for this trans-repression and that Brg1 is required in vivo to stabilize interactions between GR and NGFI-B as well as between GR and HDAC2. Whereas Brg1 is constitutively present at the POMC promoter, recruitment of GR and HDAC2 is ligand-dependent and results in histone H4 deacetylation of the POMC locus. In addition, GR-dependent repression inhibits promoter clearance by RNA polymerase II. Thus, corecruitment of repressor and activator at the promoter and chromatin modification jointly contribute to trans-repression initiated by direct interactions between GR and NGFI-B. Loss of Brg1 or HDAC2 should therefore produce Gc resistance, and we show that approximately 50% of Gc-resistant human and dog corticotroph adenomas, which are the hallmark of Cushing disease, are deficient in nuclear expression of either protein. In addition to providing a molecular basis for Gc resistance, these deficiencies may also contribute to the tumorigenic process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043312      PMCID: PMC1619949          DOI: 10.1101/gad.1444606

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  51 in total

Review 1.  Diagnosis and complications of Cushing's syndrome: a consensus statement.

Authors:  G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

Review 2.  The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression.

Authors:  Karolien De Bosscher; Wim Vanden Berghe; Guy Haegeman
Journal:  Endocr Rev       Date:  2003-08       Impact factor: 19.871

3.  The T-box factor Tpit recruits SRC/p160 co-activators and mediates hormone action.

Authors:  Mario Maira; Catherine Couture; Gwendal Le Martelot; Anne-Marie Pulichino; Steve Bilodeau; Jacques Drouin
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

4.  Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs.

Authors:  Sophie Vallette-Kasic; Dominique Figarella-Branger; Michel Grino; Anne-Marie Pulichino; Henry Dufour; François Grisoli; Alain Enjalbert; Jacques Drouin; Thierry Brue
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

5.  mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad.

Authors:  Sharmistha Pal; Romy Yun; Antara Datta; Lynne Lacomis; Hediye Erdjument-Bromage; Jitendra Kumar; Paul Tempst; Saïd Sif
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

6.  Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector.

Authors:  Marc van de Wetering; Irma Oving; Vanesa Muncan; Menno Tjon Pon Fong; Helen Brantjes; Dik van Leenen; Frank C P Holstege; Thijn R Brummelkamp; Reuven Agami; Hans Clevers
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

7.  Localized recruitment of a chromatin-remodeling activity by an activator in vivo drives transcriptional elongation.

Authors:  Laura L Corey; Christine S Weirich; Ivor J Benjamin; Robert E Kingston
Journal:  Genes Dev       Date:  2003-06-01       Impact factor: 11.361

8.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

9.  Dimer-specific potentiation of NGFI-B (Nur77) transcriptional activity by the protein kinase A pathway and AF-1-dependent coactivator recruitment.

Authors:  Mario Maira; Christine Martens; Eric Batsché; Yves Gauthier; Jacques Drouin
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

10.  Tpit determines alternate fates during pituitary cell differentiation.

Authors:  Anne-Marie Pulichino; Sophie Vallette-Kasic; Judy Peih-Ying Tsai; Catherine Couture; Yves Gauthier; Jacques Drouin
Journal:  Genes Dev       Date:  2003-03-15       Impact factor: 11.361

View more
  74 in total

1.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.

Authors:  C A Stratakis; M A Tichomirowa; S Boikos; M F Azevedo; M Lodish; M Martari; S Verma; A F Daly; M Raygada; M F Keil; J Papademetriou; L Drori-Herishanu; A Horvath; K M Tsang; M Nesterova; S Franklin; J-F Vanbellinghen; V Bours; R Salvatori; A Beckers
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

Review 2.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

Review 3.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

4.  A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease.

Authors:  Mathias Riebold; Christian Kozany; Lee Freiburger; Michael Sattler; Michael Buchfelder; Felix Hausch; Günter K Stalla; Marcelo Paez-Pereda
Journal:  Nat Med       Date:  2015-02-09       Impact factor: 53.440

Review 5.  Minireview: Conversing with chromatin: the language of nuclear receptors.

Authors:  Simon C Biddie; Sam John
Journal:  Mol Endocrinol       Date:  2013-01-01

Review 6.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 7.  The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases.

Authors:  Ioanna Petta; Lien Dejager; Marlies Ballegeer; Sam Lievens; Jan Tavernier; Karolien De Bosscher; Claude Libert
Journal:  Microbiol Mol Biol Rev       Date:  2016-05-11       Impact factor: 11.056

Review 8.  Cushing's syndrome: from physiological principles to diagnosis and clinical care.

Authors:  Hershel Raff; Ty Carroll
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

9.  Developmental dependence on NurRE and EboxNeuro for expression of pituitary proopiomelanocortin.

Authors:  Pierre-Luc Lavoie; Lionel Budry; Aurélio Balsalobre; Jacques Drouin
Journal:  Mol Endocrinol       Date:  2008-04-03

10.  Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis.

Authors:  Geert van Loo; Mozes Sze; Nadia Bougarne; Jelle Praet; Conor Mc Guire; Andrea Ullrich; Guy Haegeman; Marco Prinz; Rudi Beyaert; Karolien De Bosscher
Journal:  Mol Endocrinol       Date:  2009-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.